ENDRA Life Sciences Inc. (NDRA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 150K 300K 450K Q3 '21: 275.6K Q4 '21: 382.1K Q1 '22: 339.9K Q2 '22: 342K Q3 '22: 420.4K Q4 '22: 326.8K Q1 '23: 181.6K Q2 '23: 247.8K Q3 '23: 243.3K Q4 '23: 147.8K Q1 '24: 238.7K Q2 '24: 163K Q3 '24: 83.2K Q4 '24: 86.3K Q1 '25: 69K Q2 '25: 68.8K Q3 '25: 45.3K Q4 '25: 6.4K Q1 '26: 4.3K Q2 '26: 5.8K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

0 100K 200K 300K Q3 '16: 0 Q4 '16: 279.7K Q1 '17: 0 Q2 '17: 6.3K Q3 '17: 168.7K Q4 '17: 3.8K Q1 '18: 6.2K Q2 '18: 0 Q3 '18: 0 Q4 '18: 0 Q1 '19: 0 Q2 '19: 0 Q3 '19: 0 Q4 '19: 0 Q4 '16 Q2 '17 Q4 '17 Q2 '18 Q4 '18 Q2 '19 Q4 '19

Operating Income Quarterly

-4.5M -3M -1.5M 0 1.5M 3M 4.5M Q3 '21: -2.7M Q4 '21: -3.1M Q1 '22: -2.9M Q2 '22: -3.6M Q3 '22: -3.4M Q4 '22: -3.3M Q1 '23: -2.9M Q2 '23: -3M Q3 '23: -3.1M Q4 '23: -1.5M Q1 '24: -2.8M Q2 '24: -2.2M Q3 '24: -1.5M Q4 '24: -4.3M Q1 '25: -1.5M Q2 '25: -1.3M Q3 '25: -1.4M Q4 '25: -1.6M Q1 '26: -2.2M Q2 '26: -1.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-4.5M -3M -1.5M 0 1.5M 3M 4.5M Q3 '21: -2.7M Q4 '21: -3.1M Q1 '22: -2.9M Q2 '22: -3.6M Q3 '22: -3.4M Q4 '22: -3.3M Q1 '23: -2.9M Q2 '23: -2.6M Q3 '23: -3.1M Q4 '23: -1.5M Q1 '24: -2.8M Q2 '24: -2.2M Q3 '24: -2.4M Q4 '24: -4.1M Q1 '25: -1M Q2 '25: -1.2M Q3 '25: -1.6M Q4 '25: -3.2M Q1 '26: -1.3M Q2 '26: 159.9K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 50K 100K 150K Q2 '17: 51.4K Q3 '17: 118.3K Q1 '18: 0 Q2 '18: 0 Q3 '18: 0 Q4 '18: 0 Q1 '19: 0 Q2 '19: 0 Q3 '19: 0 Q4 '19: 0 Q3 '17 Q2 '18 Q4 '18 Q2 '19 Q4 '19

Operating Cash Flow Quarterly

-4.5M -3M -1.5M 0 1.5M 3M 4.5M Q3 '21: -2.7M Q4 '21: -2.7M Q1 '22: -3.1M Q2 '22: -3.3M Q3 '22: -3.2M Q4 '22: -3.1M Q1 '23: -2.5M Q2 '23: -2.3M Q3 '23: -2.6M Q4 '23: -2.2M Q1 '24: -2.1M Q2 '24: -2.1M Q3 '24: -1.7M Q4 '24: -1.5M Q1 '25: -1.3M Q2 '25: -1.1M Q3 '25: -1.2M Q4 '25: -1.6M Q1 '26: -1.1M Q2 '26: -927.6K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-4.5M -3M -1.5M 0 1.5M 3M 4.5M Q1 '21: -3M Q2 '21: -2.8M Q3 '21: -2.7M Q4 '21: -2.7M Q1 '22: -3.2M Q2 '22: -3.4M Q3 '22: -3.3M Q4 '22: -3.1M Q1 '23: -2.5M Q2 '23: -2.3M Q3 '23: -2.6M Q4 '23: -2.2M Q1 '24: -2.2M Q2 '24: -2.1M Q3 '24: -1.7M Q4 '24: -1.5M Q1 '25: -1.3M Q2 '25: -1.1M Q3 '25: -1.2M Q4 '25: -1.6M Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 900K 1.8M 2.7M Q3 '24: 246.8K Q1 '25: 557.6K Q2 '25: 717.1K Q3 '25: 761.2K Q1 '26: 1.2M Q2 '26: 2.5M Q3 '24 Q1 '25 Q2 '25 Q3 '25 Q1 '26 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-10.50 -7.00 -3.50 0.00 3.50 7.00 10.50 Q3 '17: -2.81 Q4 '17: -2.50 Q1 '18: -2.19 Q2 '18: -2.07 Q3 '18: -2.54 Q4 '18: -2.17 Q1 '19: -1.82 Q2 '19: -1.66 Q3 '19: -1.42 Q4 '19: -2.34 Q1 '20: -2.26 Q2 '20: -2.15 Q3 '20: -1.84 Q4 '20: -0.86 Q1 '21: -0.63 Q2 '21: -0.51 Q3 '21: -0.42 Q4 '25: -8.92 Q1 '26: -8.15 Q2 '26: -6.38 Q4 '17 Q3 '18 Q2 '19 Q1 '20 Q4 '20 Q3 '21 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.